Early aspirin use and the development of cardiac allograft vasculopathy.

[1]  A. Vallakati,et al.  Impact of Statin Use After Heart Transplantation: A Meta-Analysis , 2016, Circulation. Heart failure.

[2]  Deepak L. Bhatt,et al.  Allograft Vasculopathy: The Achilles' Heel of Heart Transplantation. , 2016, Journal of the American College of Cardiology.

[3]  L. Lund,et al.  The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report--2015; Focus Theme: Early Graft Failure. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  Bingren Gao,et al.  Simvastatin combined with aspirin increases the survival time of heart allograft by activating CD4(+)CD25(+) Treg cells and enhancing vascular endothelial cell protection. , 2015, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[5]  Akshay S. Desai,et al.  Early vitamin C and E supplementation and cardiac allograft vasculopathy: 10-year follow-up from a randomized, controlled study. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  H. Bøtker,et al.  Effect of Everolimus Introduction on Cardiac Allograft Vasculopathy—Results of a Randomized, Multicenter Trial , 2011, Transplantation.

[7]  Clive Lewis,et al.  The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  R. Starling,et al.  International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  Elizabeth A Stuart,et al.  Improving propensity score weighting using machine learning , 2010, Statistics in medicine.

[10]  A. Burke,et al.  Tobacco Smoke Exposure in Either the Donor or Recipient Before Transplantation Accelerates Cardiac Allograft Rejection, Vascular Inflammation, and Graft Loss , 2009, Circulation.

[11]  M. Weis,et al.  Cardiac allograft vasculopathy: recent developments. , 2008, Circulation.

[12]  D. Renlund,et al.  Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  B. Narasimhan,et al.  Acute Rejection and Cardiac Allograft Vascular Disease Is Reduced by Suppression of Subclinical Cytomegalovirus Infection , 2006, Transplantation.

[14]  M. Mehra,et al.  Contemporary Concepts in Prevention and Treatment of Cardiac Allograft Vasculopathy , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  M. Olschewski,et al.  LOW-DOSE ASPIRIN THERAPY IS ASSOCIATED WITH IMPROVED ALLOGRAFT FUNCTION AND PROLONGED ALLOGRAFT SURVIVAL AFTER KIDNEY TRANSPLANTATION , 2004, Transplantation.

[16]  M. Mehra,et al.  Metaanalysis of statins and survival in de novo cardiac transplantation. , 2004, Transplantation proceedings.

[17]  H. Valantine.  Cardiac allograft vasculopathy after heart transplantation: risk factors and management. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  J. Kjekshus,et al.  Platelet activation in heart transplant recipients , 2004 .

[19]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[20]  K. Endresen,et al.  Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. , 2003, Journal of the American College of Cardiology.

[21]  D. Burkhoff,et al.  Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy , 2003, Circulation.

[22]  P. Ganz,et al.  Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial , 2002, The Lancet.

[23]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[24]  G. Steinbeck,et al.  Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. , 1997, Circulation.

[25]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[26]  M. Mehra,et al.  An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. , 1995, The American journal of cardiology.

[27]  M. Ovize,et al.  Increased platelet aggregation after heart transplantation: influence of aspirin. , 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.